Veronese, Nicola
Shivappa, Nitin
Stubbs, Brendon
Smith, Toby
Hébert, James R.
Cooper, Cyrus
Guglielmi, Giuseppe
Reginster, Jean-Yves
Rizzoli, Renè
Maggi, Stefania
Funding for this research was provided by:
National Institutes of Health
Merck Research Laboratories
Novartis Pharmaceuticals Corporation
GlaxoSmithKline
Pfizer
Article History
Received: 7 June 2017
Accepted: 22 November 2017
First Online: 5 December 2017
Compliance with ethical standards
:
: The OAI is a public–private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; and N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. NS and JRH were supported by the United States National Institute for Diabetes, Digestive and Kidney Diseases (Grant No. R44DK103377). Sponsor’s role: the sponsors had no role in the design, methods, subject recruitment, data collection, analysis, or preparation of this paper.